Global market for biosimilars predicted to reach $2.45bln in 2013

Dec. 6, 2013 - PRLog -- The biosimilars market has received a lot of attention over the past decade, most notably in the last five years, due to multiple factors. First, many of the top selling pharmaceutical products are biologics, with products such as Humira, Remicade, Herceptin and Rituxan all well over the “blockbuster” level of $1B in dose sales globally, creating financial incentive for companies to develop biosimilar versions to capture market share. The global market for biosimilars is predicted to reach $2.45bn this year, accounting for around 2 per cent of the total pharmaceutical market, according to Visiongain, which says the roll out of mAb biosimilars will drive growth out to 2023.
(Source: Thomson Reuters, What to make of the Biosimilars Market?, 2013)

SMi's masterclass hosted by Interpharm Consultancy, will address the common pitfalls in and around biosimilar regulatory requirements in both Europe and the US. Case study led and extremely informative, Peter Wittner looks to help identify both successful and unsuccessful applications in regards to biosimilar regulatory approval in a bid to better inform attendees of how they might approach different markets.

--Ends--

Masterclass Host

Peter Wittner, Senior Consultant, Interpharm Consultancy

Peter Wittner, B.Sc., is an independent consultant specialising in the commercial aspects of generics with more than 30 years’ pharmaceutical experience. Before starting his own business, Peter headed the European sales and marketing departments of the UK generics companies Evans Medical and H.N, Norton, Which later became part of IVAX.

For more information please visit: http://www.smi-online.co.uk/biosimilars-regulation21.asp
Alternatively please contact: Fateja Begum, fbegum@smi-online.co.uk (mailto:agibbons@smi-online.co.uk) | +44 207 827 6184